PMC7383634_01
Abdominal aorta atheromatous plaque (arrowhead) at (a) nivolumab start and (b) resolution after treatment.
10.1177_1758835920913801-fig1.jpg
PMC7383634_01_10.1177_1758835920913801-fig1.jpg
fig1-1758835920913801
Before treatment with nivolumab, a CT scan demonstrated a complicated atheromatous plaque in the abdominal aorta wall (Figure 1a), that almost completely resolved while on nivolumab (Figure 1b), as previously reported.
Thoracic aorta atheromatous plaque (arrowhead) at (a) atezolizumab start and (b) resolution after 4 months of treatment.
10.1177_1758835920913801-fig2.jpg
PMC7383634_01_10.1177_1758835920913801-fig2.jpg
fig2-1758835920913801
At the time atezolizumab was started, a computed tomography (CT) scan demonstrated the appearance of a new complicated atheromatous plaque in the thoracic aorta (Figure 2a). Interestingly, after 4 months of atezolizumab, the thoracic aorta plaque considerably improved again until nearly complete resolution (Figure 2b).
Pathologic soft tissue at right hilum (arrowhead) at (a) atezolizumab start and (b) its reduction after 4 months of treatment consisting with disease response.
10.1177_1758835920913801-fig3.jpg
PMC7383634_01_10.1177_1758835920913801-fig3.jpg
fig3-1758835920913801
In addition, partial response of disease was observed (Figure 3) so the patient is still on treatment.